Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Human microvascular lymphatic and blood endothelial cells produce fibrillin: deposition patterns and quantitative analysis.

Rossi A, Gabbrielli E, Villano M, Messina M, Ferrara F, Weber E.

J Anat. 2010 Dec;217(6):705-14. doi: 10.1111/j.1469-7580.2010.01306.x. Epub 2010 Oct 11.

2.

Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.

Nistala H, Lee-Arteaga S, Carta L, Cook JR, Smaldone S, Siciliano G, Rifkin AN, Dietz HC, Rifkin DB, Ramirez F.

Hum Mol Genet. 2010 Dec 15;19(24):4790-8. doi: 10.1093/hmg/ddq409. Epub 2010 Sep 24. Erratum in: Hum Mol Genet. 2014 Nov 15;23(22):6137.

3.

Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation.

Nistala H, Lee-Arteaga S, Smaldone S, Siciliano G, Carta L, Ono RN, Sengle G, Arteaga-Solis E, Levasseur R, Ducy P, Sakai LY, Karsenty G, Ramirez F.

J Cell Biol. 2010 Sep 20;190(6):1107-21. doi: 10.1083/jcb.201003089.

4.

Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGF{beta} stimulation of RANKL production.

Nistala H, Lee-Arteaga S, Smaldone S, Siciliano G, Ramirez F.

J Biol Chem. 2010 Oct 29;285(44):34126-33. doi: 10.1074/jbc.M110.125328. Epub 2010 Aug 21.

5.

Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta.

Massam-Wu T, Chiu M, Choudhury R, Chaudhry SS, Baldwin AK, McGovern A, Baldock C, Shuttleworth CA, Kielty CM.

J Cell Sci. 2010 Sep 1;123(Pt 17):3006-18. doi: 10.1242/jcs.073437. Epub 2010 Aug 10.

6.

The revised Ghent nosology for the Marfan syndrome.

Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM.

J Med Genet. 2010 Jul;47(7):476-85. doi: 10.1136/jmg.2009.072785.

PMID:
20591885
7.

In vivo studies of mutant fibrillin-1 microfibrils.

Charbonneau NL, Carlson EJ, Tufa S, Sengle G, Manalo EC, Carlberg VM, Ramirez F, Keene DR, Sakai LY.

J Biol Chem. 2010 Aug 6;285(32):24943-55. doi: 10.1074/jbc.M110.130021. Epub 2010 Jun 7.

8.

A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.

Arsenault J, Lehoux J, Lanthier L, Cabana J, Guillemette G, Lavigne P, Leduc R, Escher E.

Pharmacogenet Genomics. 2010 Jun;20(6):377-88. doi: 10.1097/FPC.0b013e32833a6d4a.

PMID:
20436376
9.

Microfibril structure masks fibrillin-2 in postnatal tissues.

Charbonneau NL, Jordan CD, Keene DR, Lee-Arteaga S, Dietz HC, Rifkin DB, Ramirez F, Sakai LY.

J Biol Chem. 2010 Jun 25;285(26):20242-51. doi: 10.1074/jbc.M109.087031. Epub 2010 Apr 19.

10.

Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome.

Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V, Chillakuri CR, Macaya D, Coucke PJ, De Paepe A, Judge DP, Wigley F, Davis EC, Mardon HJ, Handford P, Keene DR, Sakai LY, Dietz HC.

Sci Transl Med. 2010 Mar 17;2(23):23ra20. doi: 10.1126/scitranslmed.3000488.

11.

Stiff and tight skin: a rear window into fibrosis without inflammation.

Avvedimento EV, Gabrielli A.

Sci Transl Med. 2010 Mar 17;2(23):23ps13. doi: 10.1126/scitranslmed.3000949.

PMID:
20375002
12.

Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.

Distler JH, Distler O.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i48-51. doi: 10.1136/ard.2009.120196. Review.

13.

A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.

Hasegawa M, Matsushita Y, Horikawa M, Higashi K, Tomigahara Y, Kaneko H, Shirasaki F, Fujimoto M, Takehara K, Sato S.

Arthritis Rheum. 2009 Nov;60(11):3465-75. doi: 10.1002/art.24934.

14.

Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis.

Wang S, Wilkes MC, Leof EB, Hirschberg R.

Am J Physiol Renal Physiol. 2010 Jan;298(1):F142-9. doi: 10.1152/ajprenal.00320.2009. Epub 2009 Oct 21.

15.

New regulatory mechanisms of TGF-beta receptor function.

Kang JS, Liu C, Derynck R.

Trends Cell Biol. 2009 Aug;19(8):385-94. doi: 10.1016/j.tcb.2009.05.008. Epub 2009 Aug 3. Review.

PMID:
19648010
16.

Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling.

Ramirez F, Rifkin DB.

Curr Opin Cell Biol. 2009 Oct;21(5):616-22. doi: 10.1016/j.ceb.2009.05.005. Epub 2009 Jun 12. Review.

17.

Biogenesis and function of fibrillin assemblies.

Ramirez F, Sakai LY.

Cell Tissue Res. 2010 Jan;339(1):71-82. doi: 10.1007/s00441-009-0822-x. Epub 2009 Jun 10. Review.

18.

Skin disease: a cardinal feature of systemic sclerosis.

Krieg T, Takehara K.

Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii14-8. doi: 10.1093/rheumatology/kep108. Review.

PMID:
19487217
19.

Stiff skin syndrome: evidence for an inflammation-independent fibrosis?

Guiducci S, Distler JH, Milia AF, Miniati I, Rogai V, Manetti M, Falcini F, Ibba-Manneschi L, Gay S, Distler O, Matucci-Cerinic M.

Rheumatology (Oxford). 2009 Jul;48(7):849-52. doi: 10.1093/rheumatology/kep118. Epub 2009 May 25.

PMID:
19468049
20.

Scleroderma.

Gabrielli A, Avvedimento EV, Krieg T.

N Engl J Med. 2009 May 7;360(19):1989-2003. doi: 10.1056/NEJMra0806188. Review. No abstract available.

PMID:
19420368

Supplemental Content

Support Center